Nugen Medical Devices
Source: NuGen.
  • NuGen Medical Devices (NGMD) announced that it intends to complete a non-brokered private placement of up to $3,600,000
  • NuGen will use the gross proceeds for working capital and for general corporate purposes
  • NuGen is an emerging specialty medical device company developing the next generation of novel drug delivery technologies
  • Nugen Medical Devices Inc. (NGMD) is holding steady, trading at C$0.22 per share at 2:20 pm ET

NuGen Medical Devices (NGMD) announced that it intends to complete a non-brokered private placement of up to $3,600,000.

The company plans to issue up to 20,000,000 units at $0.18 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.24 for twenty-four months from the closing date. The warrants are subject to the acceleration clause.

NuGen will use the gross proceeds for working capital and for general corporate purposes.

The company may pay finders fees consisting of 8 per cent cash and 8 per cent broker warrants. Each broker warrant entitles the holder to acquire one unit at $0.18 for two years from the date of issuance.

All securities issued will be subject to a statutory hold period of four months. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals. 

About NuGen Medical Devices

NuGen is an emerging specialty medical device company developing the next generation of novel drug delivery technologies. Its principal business is the research, development and commercialization of innovative needle-free injection devices and systems for the administration of subcutaneous medication.

Nugen Medical Devices Inc. (NGMD) is holding steady, trading at C$0.22 per share at 2:20 pm ET.

More From The Market Online

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.